Eli Lilly Sees FY23 Adjusted EPS Of $6.50-$6.70 Versus Prior Guidance Of $9.70-$9.90 And Consensus Of $7.97
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has revised its FY23 adjusted EPS guidance to $6.50-$6.70, down from the previous guidance of $9.70-$9.90. This is also below the consensus estimate of $7.97.
November 02, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Eli Lilly's revised FY23 adjusted EPS guidance is significantly lower than previous estimates, which could negatively impact the company's stock price in the short term.
Eli Lilly's revised FY23 adjusted EPS guidance is significantly lower than both its previous guidance and the consensus estimate. This suggests that the company's earnings may be lower than expected, which could lead to a decrease in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100